DURECT (DRRX) Competitors $0.85 +0.02 (+2.15%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DRRX vs. COYA, EDIT, CABA, MNOV, ABOS, JSPR, ME, VOR, ORMP, and ATRAShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Coya Therapeutics (COYA), Editas Medicine (EDIT), Cabaletta Bio (CABA), MediciNova (MNOV), Acumen Pharmaceuticals (ABOS), Jasper Therapeutics (JSPR), 23andMe (ME), Vor Biopharma (VOR), Oramed Pharmaceuticals (ORMP), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Coya Therapeutics Editas Medicine Cabaletta Bio MediciNova Acumen Pharmaceuticals Jasper Therapeutics 23andMe Vor Biopharma Oramed Pharmaceuticals Atara Biotherapeutics Coya Therapeutics (NASDAQ:COYA) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends. Do institutionals and insiders hold more shares of COYA or DRRX? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 9.8% of Coya Therapeutics shares are held by company insiders. Comparatively, 3.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, COYA or DRRX? Coya Therapeutics has higher earnings, but lower revenue than DURECT. Coya Therapeutics is trading at a lower price-to-earnings ratio than DURECT, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$6M14.98-$7.99M-$0.65-8.28DURECT$8.55M3.09-$27.62M-$0.61-1.39 Is COYA or DRRX more profitable? Coya Therapeutics has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Coya Therapeutics' return on equity of -31.63% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% DURECT -198.58%-300.62%-65.17% Which has more volatility and risk, COYA or DRRX? Coya Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Does the MarketBeat Community prefer COYA or DRRX? DURECT received 300 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 94.12% of users gave Coya Therapeutics an outperform vote while only 62.95% of users gave DURECT an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes1694.12% Underperform Votes15.88%DURECTOutperform Votes31662.95% Underperform Votes18637.05% Does the media prefer COYA or DRRX? In the previous week, Coya Therapeutics had 1 more articles in the media than DURECT. MarketBeat recorded 1 mentions for Coya Therapeutics and 0 mentions for DURECT. Coya Therapeutics' average media sentiment score of 1.95 beat DURECT's score of 0.89 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coya Therapeutics Very Positive DURECT Positive Do analysts prefer COYA or DRRX? Coya Therapeutics currently has a consensus price target of $16.25, suggesting a potential upside of 202.04%. DURECT has a consensus price target of $5.00, suggesting a potential upside of 488.30%. Given DURECT's higher possible upside, analysts plainly believe DURECT is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00DURECT 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryCoya Therapeutics beats DURECT on 12 of the 17 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.38M$6.52B$5.34B$9.11BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A4.4457.4913.22Price / Sales3.09310.281,275.6876.05Price / CashN/A22.6336.6032.90Price / Book1.704.964.874.58Net Income-$27.62M$154.90M$118.05M$224.84M7 Day Performance-0.01%1.38%1.50%2.37%1 Month Performance-10.54%0.44%2.55%4.40%1 Year Performance16.09%3.11%25.83%20.11% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT4.0353 of 5 stars$0.85+2.2%$5.00+488.3%+16.1%$26.38M$8.55M0.0080COYACoya Therapeutics2.7436 of 5 stars$5.92+2.6%$16.25+174.5%-9.9%$98.91M$9.55M-9.116Short Interest ↑Positive NewsEDITEditas Medicine4.5128 of 5 stars$1.20-5.2%$7.00+485.8%-84.9%$98.65M$61.76M-0.47230Short Interest ↑CABACabaletta Bio3.0437 of 5 stars$2.01-3.4%$24.38+1,112.7%-85.9%$98.24MN/A-0.9350MNOVMediciNova1.402 of 5 stars$1.99+1.5%$9.00+352.3%+22.0%$97.60M$1M-9.4810Analyst ForecastNews CoveragePositive NewsABOSAcumen Pharmaceuticals3.0296 of 5 stars$1.62-2.1%$9.33+477.9%-54.4%$97.03MN/A-1.1720Short Interest ↑JSPRJasper Therapeutics2.7557 of 5 stars$6.45-8.5%$67.75+950.4%-50.0%$96.76MN/A-1.3620Short Interest ↑ME23andMe1.5179 of 5 stars$3.66-4.7%$9.40+156.8%-74.6%$95.59M$193.26M-0.14770Analyst ForecastGap UpVORVor Biopharma2.1188 of 5 stars$1.39-10.6%$11.36+717.1%-41.3%$95.46MN/A-0.84140ORMPOramed Pharmaceuticals2.6661 of 5 stars$2.36-1.3%N/A+2.5%$95.14M$1.34M21.4510ATRAAtara Biotherapeutics4.0554 of 5 stars$16.40+5.5%$18.75+14.3%-58.6%$94.46M$100.44M-0.64165Gap Down Related Companies and Tools Related Companies COYA Competitors EDIT Competitors CABA Competitors MNOV Competitors ABOS Competitors JSPR Competitors ME Competitors VOR Competitors ORMP Competitors ATRA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRRX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
